Overview

A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis

Status:
RECRUITING
Trial end date:
2026-01-30
Target enrollment:
Participant gender:
Summary
The study is designed to evaluate the Safety, Tolerability and Pharmacokinetics of ATB1651 in participants with mild to moderate onychomycosis
Phase:
PHASE2
Details
Lead Sponsor:
AmtixBio Co., Ltd.